United States News Todas as matérias

uniQure (NASDAQ:QURE) reported additional Phase I/II data for ifezuntirgene inilparvovec, its investigational gene therapy for Huntington’s disease, with follow-up results extending to 36 and 48 months.

Invivyd (NASDAQ:IVVD) reported Phase 3 LIBERTY trial results showing that its investigational COVID-19 antibody product VYD2311 demonstrated fewer reported adverse events compared with an mRNA COVID-19 vaccine.

IM Cannabis (NASDAQ:IMCC) completed the sale of IMC Holdings to Slil, following a transaction that included a previously paid C$3 million payment as part of the consideration.

Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Zepbound 10 mg and 15 mg were associated with greater weight loss than Wegovy HD 7.2 mg in adults with obesity.

Scholastic (NASDAQ:SCHL) signed a definitive agreement to acquire Cottage Door Press for approximately $71 million, subject to customary purchase price adjustments.

Scorpio Tankers (NYSE:STNG) announced agreements to sell three product tankers and acquire four newbuilding vessels as part of its fleet management strategy.

Parsons (NYSE:PSN) won an initial $85 million agreement to provide advisory services for the development of the U.S. Space Command’s new headquarters at Redstone Arsenal in Alabama.

GFL Environmental (NYSE:GFL) declared a third-quarter 2026 cash dividend of US$0.0169 per subordinate and multiple voting share.

Westlake (NYSE:WLK) announced plans to close its PVC manufacturing facility in Cologne, Germany, during the first quarter of 2027 as part of efforts to improve profitability in its European chlorovinyl operations.

Amcor (NYSE:AMCR) announced that Board Chair Graeme Liebelt will retire from the company’s board, with Tom Long set to succeed him following the annual meeting on November 11, 2026.

iHuman (NYSE:IH) reported second-quarter 2026 financial results, with revenue and user numbers declining while the company moved to a net loss compared with the prior-year period.

CarMax (NYSE:KMX) reported results for the second quarter ended August 31, 2026, with higher vehicle sales, revenue growth, and improved earnings.

Kura Oncology (NASDAQ:KURA) and Caspian Therapeutics presented preclinical findings for KO-7246, an investigational diabetes treatment candidate, at the European Association for the Study of Diabetes (EASD) meeting in Milan.

FreeCast (NASDAQ:CAST) filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, highlighting progress in its transition from technology development toward commercial deployment of its Platform-as-a-Service (PaaS) strategy.

Tesla’s (NASDAQ:TSLA) Full Self-Driving (FSD) system is facing regulatory scrutiny in Europe after the European Transport Safety Council (ETSC) urged European Union member states to reject approval of the driver-assistance technology.

Jaguar Health (NASDAQ:JAGX) announced that an abstract covering preliminary results from an adult short bowel syndrome study has been accepted for presentation at the American College of Gastroenterology (ACG) 2026 meeting.

Pearson (NYSE:PSO) agreed to acquire Workera, a company that provides AI-powered workforce skills assessment solutions for enterprises.

HUTCHMED (NASDAQ:HCM) announced that AstraZeneca (NASDAQ:AZN) submitted a U.S. regulatory application for ORPATHYS in combination with TAGRISSO for patients with MET-driven EGFR-mutated non-small cell lung cancer.

Quantum-Si (NASDAQ:QSI) reported interim results showing that its developmental Proteus protein-sequencing platform outperformed its Platinum Pro system across multiple performance measures.

Hormel Foods (NYSE:HRL) declared a quarterly common-stock dividend of $0.2925 per share, continuing the company’s long history of returning capital to shareholders.

Evotec (NASDAQ:EVO) announced that Chief Scientific Officer Cord Dohrmann will step down from his role on September 30, 2026, by mutual consent.

Novo Nordisk (NYSE:NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a transaction valued at up to $2.6 billion.

Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Foundayo 17.2 mg produced greater weight loss and A1C reduction than oral semaglutide 25 mg in adults with type 2 diabetes.

Opengear, a Digi International company (NASDAQ:DGII), signed its first pan-European distribution agreement with Ingram Micro to expand access to its out-of-band management solutions across Europe.